Agathocleous, Agathoclis <br/><br/>
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.  [electronic resource] 

 -  British journal of haematology  Nov 2010 
 - 346-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2010.08340.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Lymphoma, Follicular--drug therapy<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Lymphoproliferative Disorders--drug therapy<br/>Male<br/>Middle Aged<br/>Pyrazines--administration & dosage<br/>Rituximab<br/>Survival Analysis<br/>Treatment Outcome<br/>Waldenstrom Macroglobulinemia--drug therapy